Thrombophilia due to activated protein C resistance
MONDO:0008560A hemostatic disorder characterized by a poor anticoagulant response to activated protein C (APC). The activated form of Factor V (Factor Va) is more slowly degraded by activated protein C. Factor V Leiden mutation (R506Q) is the most common cause of APC resistance.
Also known as: thrombophilia 2 due to activated protein C resistance, thrombophilia due to activated protein C resistance, APC resistance, Activated Protein C resistance, Pccf deficiency, Proc cofactor deficiency, THPH2, resistance, APC
10 clinical trials for this condition and its sub-types, 5 tagged with Thrombophilia due to activated protein C resistance itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New shot aims to prevent dangerous clots in High-Risk patients
Disease control Recruiting nowThis early-stage study tests a single injection of CITY-FXI, a drug designed to lower clotting risk by targeting a protein called Factor XI. It includes healthy adults and those with Factor V Leiden or prothrombin G20210A mutations, which increase clot risk. The main goal is to c…
Phase 1 • Sponsor: City Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New study prepares those with genetic clot risk for future trials
Knowledge-focused Recruiting nowThis study enrolls 100 adults who have or may have Factor V Leiden or Prothrombin G20210A mutations, which increase the risk of blood clots. Participants undergo genetic testing to confirm their status, then attend a site visit for basic health checks like blood pressure, ECG, an…
Sponsor: Richmond Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC